Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Intellia Therapeutics (NTLA) Return on Equity (2016 - 2025)

Historic Return on Equity for Intellia Therapeutics (NTLA) over the last 10 years, with Q3 2025 value amounting to 0.61%.

  • Intellia Therapeutics' Return on Equity fell 1000.0% to 0.61% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.61%, marking a year-over-year decrease of 1000.0%. This contributed to the annual value of 0.51% for FY2024, which is 1000.0% down from last year.
  • According to the latest figures from Q3 2025, Intellia Therapeutics' Return on Equity is 0.61%, which was down 1000.0% from 0.63% recorded in Q2 2025.
  • Intellia Therapeutics' 5-year Return on Equity high stood at 0.25% for Q4 2021, and its period low was 0.63% during Q2 2025.
  • In the last 5 years, Intellia Therapeutics' Return on Equity had a median value of 0.44% in 2022 and averaged 0.43%.
  • Its Return on Equity has fluctuated over the past 5 years, first surged by 1500bps in 2021, then tumbled by -2100bps in 2022.
  • Over the past 5 years, Intellia Therapeutics' Return on Equity (Quarter) stood at 0.25% in 2021, then crashed by -76bps to 0.44% in 2022, then dropped by -2bps to 0.45% in 2023, then fell by -19bps to 0.53% in 2024, then decreased by -15bps to 0.61% in 2025.
  • Its Return on Equity was 0.61% in Q3 2025, compared to 0.63% in Q2 2025 and 0.6% in Q1 2025.